<DOC>
	<DOCNO>NCT02385721</DOCNO>
	<brief_summary>Evaluated incidence characteristic adverse event treatment Kanarb tablet .</brief_summary>
	<brief_title>A Prospective , Observational , Post-Authorization Long-term Safety Surveillance Antihypertensive Treatment With KanarbÂ® ( Fimasartan )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>Clinical diagnosis Hypertension Patients peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>